Research topics
Immune pathway articles covering inflammatory mechanisms, immune cells, signaling pathways, and disease biology in IBD research.
37 articles
The study links TXNIP/NLRP3 inflammatory signaling to disease features in an animal UC model and tests engeletin and rosuvastatin as interventions that lowered inflammatory markers—information relevant to researchers...
The study links NAD+ precursor (NMN) supplementation to changes in TGF-β–associated gene programs, intestinal immune signatures, and the gut microbiome in mouse colitis models — pathways relevant to fibrosis and...
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...
The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...
If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...
This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...
The study explores a novel, combined nanozyme + microbiome-derived vesicle approach aimed at reducing oxidative stress and modulating inflammation in IBD — mechanisms that are relevant to disease pathways and future...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Researchers are exploring natural compounds that may modulate gut microbes, barrier function, and immune signaling relevant to ulcerative colitis.
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
This study reports a new colon-targeted delivery system for unconjugated bilirubin that reduced inflammation and improved mucosal healing in a mouse model of ulcerative colitis; it could inform future drug-development...
Finding shared genes (CLDN8, ABCA12) suggests common inflammatory mechanisms between ulcerative colitis and psoriasis, which could inform future biomarkers or therapies relevant to patients with either or both...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
A treatable-traits approach could help tailor IBD care to each patient by targeting specific biological, comorbid, and psychosocial drivers of disease and quality-of-life impairment, potentially improving how we choose...
The study suggests JAK and TYK2 inhibitors can directly change epithelial inflammatory signaling and proliferation in UC, which may be relevant to healing of the gut lining and how different drugs work beyond immune...
FMT and precision microbiota therapies target the gut ecosystem, a modifiable factor in UC. For people with UC, this review explains potential mechanisms, where FMT has shown benefit in trials, and why it is still...
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are...
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...
The work models how Mycobacterium avium can provoke epithelial inflammation similar to Crohn's disease, pointing to possible molecular links between infection and CD-like pathology that could guide future research.
This review explains how genetic, microbial, immune, and stromal factors interact to cause Crohn’s disease, which helps explain why treatments often need to target specific immune pathways or biologic mechanisms....
If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
This study links an HLA gene (DRB1) to shared T cell receptor patterns in both Crohn’s disease and ulcerative colitis, suggesting common immune targets across IBD subtypes. That could help researchers identify antigens...
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
The article connects psoriasis and Crohn's disease through shared immune pathways and the gut-skin axis, which may matter because people with one condition could have signs or risks related to the other. It emphasizes...
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
